DocDollars

Biomarin Pharmaceutical Inc.

CA · United States · Reporting entity ID 100000010405

Total reported 2019–2025
$83.7M
#117 of 2,960 reporting companies — 0.1% of all reported industry payments
$15.5M in general payments across 15,259 records, plus $68.2M in research funding across 7,889 records.

How it breaks down

General payments $15,515,103
Research funding $68,220,680

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Biomarin Pharmaceutical Inc. reported $83.7M to US doctors and teaching hospitals from 2019 to 2025, ranking #117 of 2,960 reporting companies. 81% of that was research funding and 19% general payments such as consulting, speaking, food and travel. 15,259 general payment records and 7,889 research records were filed.

Common questions about Biomarin Pharmaceutical Inc.

How much has Biomarin Pharmaceutical Inc. paid US doctors?

Biomarin Pharmaceutical Inc. reported $83,735,783 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $15,515,103 in general payments, $68,220,680 in research funding.

How does Biomarin Pharmaceutical Inc. rank among drug and device companies?

It ranks #117 of 2,960 reporting entities by total reported value, about 0.1% of all industry payments in the dataset.

Does a payment from Biomarin Pharmaceutical Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.